Concord Biotech Limited (NSE:CONCORDBIO) — Stock Price
Concord Biotech Limited (NSE:CONCORDBIO) is currently trading at Rs1419.00 INR, up 3.96% today. Over the past 52 weeks, shares have ranged between Rs1014.80 and Rs1767.60. This page tracks Concord Biotech Limited's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of Concord Biotech Limited.
Concord Biotech Limited (CONCORDBIO) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Concord Biotech Limited's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Concord Biotech Limited Income Statement — Revenue, Profit & Earnings by Year
Concord Biotech Limited's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Rs12.00 Billion | Rs10.17 Billion | Rs8.53 Billion | Rs7.13 Billion | Rs6.17 Billion |
| Cost of Revenue | Rs4.32 Billion | Rs3.50 Billion | Rs1.92 Billion | Rs1.72 Billion | Rs1.17 Billion |
| Gross Profit | Rs7.68 Billion | Rs6.67 Billion | Rs6.61 Billion | Rs5.41 Billion | Rs5.00 Billion |
| Research & Development | Rs274.40 Million | Rs229.04 Million | Rs328.30 Million | Rs290.87 Million | Rs172.34 Million |
| SG&A | — | Rs111.29 Million | Rs105.02 Million | Rs105.81 Million | Rs70.94 Million |
| Total Operating Expenses | Rs1.66 Billion | Rs1.46 Billion | Rs1.43 Billion | Rs1.25 Billion | Rs699.61 Million |
| Operating Income | Rs6.02 Billion | Rs5.21 Billion | Rs5.18 Billion | Rs4.16 Billion | Rs4.30 Billion |
| EBITDA | Rs5.13 Billion | Rs4.39 Billion | Rs3.53 Billion | Rs2.78 Billion | Rs3.29 Billion |
| EBIT | Rs4.60 Billion | Rs3.87 Billion | Rs3.00 Billion | Rs2.29 Billion | Rs3.02 Billion |
| Interest Expense | Rs10.42 Million | Rs31.26 Million | Rs91.33 Million | Rs61.35 Million | Rs9.05 Million |
| Income Before Tax | Rs4.95 Billion | Rs4.13 Billion | Rs3.22 Billion | Rs2.38 Billion | Rs3.13 Billion |
| Income Tax Expense | Rs1.23 Billion | Rs1.04 Billion | Rs819.28 Million | Rs625.89 Million | Rs778.33 Million |
| Net Income | Rs3.72 Billion | Rs3.08 Billion | Rs2.40 Billion | Rs1.75 Billion | Rs2.35 Billion |
Concord Biotech Limited Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Concord Biotech Limited's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Rs20.34 Billion | Rs17.01 Billion | Rs15.14 Billion | Rs13.13 Billion | Rs11.83 Billion |
| Total Current Assets | Rs11.35 Billion | Rs8.96 Billion | Rs7.28 Billion | Rs6.33 Billion | Rs6.07 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | Rs3.17 Billion | Rs2.70 Billion | Rs1.78 Billion | Rs1.61 Billion | Rs1.96 Billion |
| Net Receivables | Rs5.22 Billion | Rs3.50 Billion | Rs3.13 Billion | Rs2.60 Billion | Rs2.13 Billion |
| Inventory | Rs2.40 Billion | Rs2.08 Billion | Rs2.12 Billion | Rs1.95 Billion | Rs1.54 Billion |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Rs2.22 Billion | Rs1.74 Billion | Rs2.24 Billion | Rs2.10 Billion | Rs1.83 Billion |
| Total Current Liabilities | Rs1.84 Billion | Rs1.42 Billion | Rs1.92 Billion | Rs1.55 Billion | Rs1.06 Billion |
| Long-term Debt | — | — | — | — | — |
| Net Debt | Rs17.86 Million | Rs-54.05 Million | Rs280.48 Million | Rs618.26 Million | Rs841.39 Million |
| Total Stockholder Equity | Rs18.13 Billion | Rs15.27 Billion | Rs12.90 Billion | Rs11.03 Billion | Rs9.99 Billion |
| Retained Earnings | Rs17.20 Billion | Rs14.05 Billion | Rs11.68 Billion | Rs9.82 Billion | Rs8.78 Billion |
Concord Biotech Limited Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Concord Biotech Limited generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rs2.47 Billion | Rs2.65 Billion | Rs2.46 Billion | Rs2.07 Billion | Rs1.67 Billion |
| Capital Expenditures | Rs1.11 Billion | Rs856.88 Million | Rs1.45 Billion | Rs1.56 Billion | Rs2.04 Billion |
| Free Cash Flow | Rs1.36 Billion | Rs1.80 Billion | Rs1.01 Billion | Rs519.70 Million | Rs-373.59 Million |
| Investing Cash Flow | Rs-1.63 Billion | Rs-1.55 Billion | Rs-1.58 Billion | Rs-1.12 Billion | Rs-1.95 Billion |
| Financing Cash Flow | Rs-986.67 Million | Rs-992.15 Million | Rs-852.19 Million | Rs-1.00 Billion | Rs311.24 Million |
| Dividends Paid | Rs-915.39 Million | Rs-714.53 Million | Rs-535.63 Million | Rs-705.21 Million | Rs57.06 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Rs543.74 Million | Rs535.91 Million | Rs540.32 Million | Rs500.50 Million | Rs275.23 Million |
| Change in Cash | Rs-196.34 Million | Rs116.43 Million | Rs28.32 Million | Rs-44.77 Million | Rs27.36 Million |
Concord Biotech Limited Earnings History — EPS Actual vs. Analyst Estimates
Track Concord Biotech Limited's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 13, 2025 | 6.03 | 4.80 | +25.63% |
| Jun 30, 2025 | 4.21 | 6.30 | -33.17% |
| May 29, 2025 | 13.42 | 10.20 | +31.57% |
| Feb 13, 2025 | 7.26 | 8.90 | -18.43% |
| Nov 11, 2024 | 9.15 | 7.40 | +23.65% |
| Aug 09, 2024 | 5.70 | 6.50 | -12.31% |
| May 24, 2024 | 9.08 | 9.10 | -0.22% |
| Feb 08, 2024 | 7.41 | 7.80 | -5.00% |